TY - JOUR
T1 - Prevalence of chronic kidney disease in Asia
T2 - A systematic review and analysis
AU - Liyanage, Thaminda
AU - Toyama, Tadashi
AU - Hockham, Carinna
AU - Ninomiya, Toshiharu
AU - Perkovic, Vlado
AU - Woodward, Mark
AU - Fukagawa, Masafumi
AU - Matsushita, Kunihiro
AU - Praditpornsilpa, Kearkiat
AU - Hooi, Lai Seong
AU - Iseki, Kunitoshi
AU - Lin, Ming Yen
AU - Stirnadel-Farrant, Heide A.
AU - Jha, Vivekanand
AU - Jun, Min
N1 - Funding Information:
Competing interests TL, TT and KP have no relevant conflicts of interests to declare. MW declares consulting work for Amgen, Kyowa Kirin and Freeline, and was funded by an Australian National Health and Medical Research Council Investigator and Programme Grants. VP reports receiving personal fees for Advisory Boards or Scientific Presentations from Retrophin, Janssen, Merck, and Servier. VP also reports receiving fees for Advisory Boards, Steering Committee roles, or Scientific Presentations from Abbvie, Astellas, Astra Zeneca, Bayer, Baxter, BMS, Boehringer Ingelheim, Dimerix, Durect, Eli Lilly, Gilead, GSK, Janssen, Merck, Mitsubishi Tanabe, Novartis, Novo Nordisk, Pfizer, Pharmalink, Relypsa, Retrophin, Sanofi, Servier, Vifor and Tricida. HS-F was a full-time employee and shareholder of GlaxoSmithKline. VJ reports grant funding from NephroPlus, Baxter Healthcare and GSK and speaker fees and honoraria from Baxter Healthcare and AstraZeneca (all monies paid to the employing organisation). MJ reports receiving research support from (1) the Australian National Health and Medical Research Council and (2) VentureWise (a wholly-owned subsidiary of NPS MedicineWise) to conduct a project funded by AstraZeneca.
Funding Information:
Funding This study was funded by a research grant from GlaxoSmithKline (GSK) Limited. TL, TT, TN, VP, VJ, and MJ had access to all data. MJ and VJ were responsible for the decision to submit the manuscript.
Funding Information:
Twitter Carinna Hockham @carinnahockham, Lai Seong Hooi @laihooi1 and Vivekanand Jha @vjha126 Acknowledgements TL was supported by an Australian Postgraduate Award. TT is supported by the Japan Society for the Promotion of Science Programme for Fostering Globally Talented Researchers. MJ was supported by a Scientia Fellowship from UNSW Sydney, Australia.
Publisher Copyright:
© Author(s) (or their employer(s)) 2022.
PY - 2022/1/25
Y1 - 2022/1/25
N2 - Introduction The burden of chronic kidney disease (CKD) is growing rapidly around the world. However, there is limited information on the overall regional prevalence of CKD, as well as the variations in national prevalence within Asia. We aimed to consolidate available data and quantify estimates of the CKD burden in this region. Methods We systematically searched MEDLINE, Embase and Google Scholar for observational studies and contacted national experts to estimate CKD prevalence in countries of Asia (Eastern, Southern and South Eastern Asia). CKD was defined as estimated glomerular filtration rate (eGFR) <60 mL/min/1.73 m 2 or the presence of proteinuria. For countries without reported data, we estimated CKD prevalence using agglomerative average-linkage hierarchical clustering, based on country-level risk factors and random effects meta-analysis within clusters. Published CKD prevalence data were obtained for 16 countries (of the 26 countries in the region) and estimates were made for 10 countries. Results There was substantial variation in overall and advanced (eGFR <30 mL/min/1.73 m 2) CKD prevalence (range: 7.0%-34.3% and 0.1%-17.0%, respectively). Up to an estimated 434.3 million (95% CI 350.2 to 519.7) adults have CKD in Asia, including up to 65.6 million (95% CI 42.2 to 94.9) who have advanced CKD. The greatest number of adults living with CKD were in China (up to 159.8 million, 95% CI 146.6 to 174.1) and India (up to 140.2 million, 95% CI 110.7 to 169.7), collectively having 69.1% of the total number of adults with CKD in the region. Conclusion The large number of people with CKD, and the substantial number with advanced CKD, show the need for urgent collaborative action in Asia to prevent and manage CKD and its complications.
AB - Introduction The burden of chronic kidney disease (CKD) is growing rapidly around the world. However, there is limited information on the overall regional prevalence of CKD, as well as the variations in national prevalence within Asia. We aimed to consolidate available data and quantify estimates of the CKD burden in this region. Methods We systematically searched MEDLINE, Embase and Google Scholar for observational studies and contacted national experts to estimate CKD prevalence in countries of Asia (Eastern, Southern and South Eastern Asia). CKD was defined as estimated glomerular filtration rate (eGFR) <60 mL/min/1.73 m 2 or the presence of proteinuria. For countries without reported data, we estimated CKD prevalence using agglomerative average-linkage hierarchical clustering, based on country-level risk factors and random effects meta-analysis within clusters. Published CKD prevalence data were obtained for 16 countries (of the 26 countries in the region) and estimates were made for 10 countries. Results There was substantial variation in overall and advanced (eGFR <30 mL/min/1.73 m 2) CKD prevalence (range: 7.0%-34.3% and 0.1%-17.0%, respectively). Up to an estimated 434.3 million (95% CI 350.2 to 519.7) adults have CKD in Asia, including up to 65.6 million (95% CI 42.2 to 94.9) who have advanced CKD. The greatest number of adults living with CKD were in China (up to 159.8 million, 95% CI 146.6 to 174.1) and India (up to 140.2 million, 95% CI 110.7 to 169.7), collectively having 69.1% of the total number of adults with CKD in the region. Conclusion The large number of people with CKD, and the substantial number with advanced CKD, show the need for urgent collaborative action in Asia to prevent and manage CKD and its complications.
UR - http://www.scopus.com/inward/record.url?scp=85124104119&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85124104119&partnerID=8YFLogxK
U2 - 10.1136/bmjgh-2021-007525
DO - 10.1136/bmjgh-2021-007525
M3 - Article
AN - SCOPUS:85124104119
SN - 2059-7908
VL - 7
JO - BMJ Global Health
JF - BMJ Global Health
IS - 1
M1 - e007525
ER -